Modified gefitinib conjugated Fe(3)O(4) NPs for improved delivery of chemo drugs following an image-guided mechanistic study of inner vs. outer tumor uptake for the treatment of non-small cell lung cancer

Gefitinib (GEF) is an FDA-approved anti-cancer drug for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC). However, the efficacy of anticancer drugs is limited due to their non-specificity, lower accumulation at target sites, and systemic toxicity. Herein, we su...

Descripción completa

Detalles Bibliográficos
Autores principales: Thangudu, Suresh, Tsai, Ching-Yi, Lin, Wei-Che, Su, Chia-Hao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Bioengineering and Biotechnology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10591449/
https://www.ncbi.nlm.nih.gov/pubmed/37877039
http://dx.doi.org/10.3389/fbioe.2023.1272492

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10591449/
https://www.ncbi.nlm.nih.gov/pubmed/37877039
http://dx.doi.org/10.3389/fbioe.2023.1272492

Ejemplares similares